Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
H.R. 7902 would remove federal FDA approval for mifepristone (RU-486, marketed as Mifeprex) when it is used for terminating an intrauterine pregnancy, and it would treat continued interstate distribution as a federal violation after a 14-day delay from enactment. The bill also would require that mifepristone be treated as “misbranded” if its labeling allows for use for intrauterine pregnancy termination or use in combination with another drug for that purpose. In addition, it would create a new federal civil “tort” pathway for people harmed by the drug, allowing lawsuits against manufacturers that make mifepristone for this use, covering both physical injury and certain mental health harms, with potential compensatory and punitive damages plus attorney’s fees. This new lawsuit right would take effect 90 days after enactment, and it would not block or replace other state-law remedies. The bill includes no specific funding amounts, but it establishes the liability framework and timing for when the changes take effect.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.